23:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb  Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in...
22:28 , Jul 2, 2019 |  BC Extra  |  Company News

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada  FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure prophylaxis (PrEP), which required manufacturers to provide educational...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
01:12 , Jun 28, 2019 |  BC Extra  |  Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
22:19 , Jun 19, 2019 |  BC Extra  |  Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS  Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:46 , Apr 15, 2019 |  BC Extra  |  Company News

$1.2B Catalent-Paragon deal latest in race to lock up gene therapy manufacturing

The 6x multiple Catalent is paying for gene therapy manufacturer Paragon Bioservices suggests buyers believe gene therapy companies will remain heavily dependent on outsourcing as new therapies are approved in the next few years. Catalent...
00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
17:58 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Biohaven's orally dissolving tablet meets in Phase III for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said its orally dissolving tablet (ODT) formulation of rimegepant met the co-primary endpoints in the Phase III BHV3000-303 trial for the acute treatment of migraine. The company updated its...